Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer

Inclusion Criteria: * Patients are required to have pathologically confirmed adenocarcinoma or squamous cell carcinoma of the esophagus, gastroesophageal junction, or stomach. * Patients may have mediastinal, celiac adenopathy, peri-portal and regional gastric lymphadenopathy. * There must be no evidence of distant organ metastases. * No prior radiation for gastric or esophageal cancer. * Patients must be \> 18 years of age, and nonpregnant * Patients must have an ANC \> 1,500/ul, platelets \> 100,000/ul, creatinine \< 2 x upper limit normal (ULN) and bilirubin \< 1.5 x ULN, and AST \< 3 x ULN. * ECOG performance status 0-2. * Patients must not have significant infection or other coexistent medical condition that would preclude protocol therapy. * Female patients, must either be not of child bearing potential or have a negative pregnancy test within 7 days of starting study treatment. Patients are considered not of child bearing potential if they are surgically sterile (they have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or they are postmenopausal. Pregnant or lactating females are not eligible. * All patients must sign informed consent Exclusion Criteria: Any of the following criteria will make the patient ineligible to participate in this study: * Acute hepatitis or AIDS. * Active or uncontrolled infection. * Significant history of uncontrolled cardiac disease; i.e., uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, and cardiomyopathy with decreased ejection fraction. * Prior therapy which specifically and directly targets the EGFR pathway. * Prior severe infusion reaction to a monoclonal antibody. * Any concurrent chemotherapy not indicated in the study protocol or any other investigational agent(s).